Literature DB >> 15604261

Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells.

Angela Papageorgiou1, Laura Lashinger, Randall Millikan, H Barton Grossman, William Benedict, Colin P N Dinney, David J McConkey.   

Abstract

Immunomodulators such as Bacillus Calmette-Guerin and interferon are clinically active in transitional cell carcinoma of the bladder, but their mechanisms of action remain unclear. Here we investigated the effects of IFNalpha on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and apoptosis in a panel of 20 human bladder cancer cell lines. Six (30%) displayed significant DNA fragmentation in response to increasing concentrations of IFNalpha (10-100,000 units/mL). In these lines IFNalpha induced early activation of caspase-8, and DNA fragmentation was blocked by a caspase-8-selective inhibitor (IETDfmk), consistent with the involvement of death receptor(s) in cell death. IFNalpha stimulated marked increases in TRAIL mRNA and protein in the majority of IFN-sensitive and IFN-resistant cell lines. A blocking anti-TRAIL antibody significantly inhibited IFN-induced DNA fragmentation in four of six IFN-sensitive cell lines, confirming that TRAIL played a direct role in cell death. Bortezomib (PS-341, Velcade), a potent TRAIL-sensitizing agent, increased sensitivity to IFNalpha in two of the IFN-resistant cell lines that produced large amounts of TRAIL in response to IFN treatment. Our data show that IFN-induced apoptosis in bladder cancer cells frequently involves autocrine TRAIL production. Combination therapy strategies aimed at overcoming TRAIL resistance may be very effective in restoring IFN sensitivity in a subset of human bladder tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15604261     DOI: 10.1158/0008-5472.CAN-04-1909

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Direct gene transfer of adenoviral-mediated interferon α into human bladder cancer cells but not the bystander factors produced induces endoplasmic reticulum stress-related cytotoxicity.

Authors:  X-Q Zhang; Z Yang; W F Benedict
Journal:  Cancer Gene Ther       Date:  2010-12-24       Impact factor: 5.987

2.  Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.

Authors:  Abel Torres; Leslie Storey; Makala Anders; Richard L Miller; Barbara J Bulbulian; Jizhong Jin; Shalini Raghavan; James Lee; Herbert B Slade; Woubalem Birmachu
Journal:  J Transl Med       Date:  2007-01-26       Impact factor: 5.531

Review 3.  Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.

Authors:  David J McConkey; Woonyoung Choi; Lauren Marquis; Frances Martin; Michael B Williams; Jay Shah; Robert Svatek; Aditi Das; Liana Adam; Ashish Kamat; Arlene Siefker-Radtke; Colin Dinney
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

Review 4.  Immune therapies in non-muscle invasive bladder cancer.

Authors:  Philip L Ho; Stephen B Williams; Ashish M Kamat
Journal:  Curr Treat Options Oncol       Date:  2015-02

5.  Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.

Authors:  Adam R Metwalli; Sanaz Khanbolooki; Goodwin Jinesh; Debasish Sundi; Jay B Shah; Marissa Shrader; Woonyoung Choi; Laura M Lashinger; Srinivas Chunduru; David J McConkey; Mark McKinlay; Ashish M Kamat
Journal:  Cancer Biol Ther       Date:  2010-11-01       Impact factor: 4.742

6.  Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.

Authors:  Neal D Shore; Stephen A Boorjian; Daniel J Canter; Kenneth Ogan; Lawrence I Karsh; Tracy M Downs; Leonard G Gomella; Ashish M Kamat; Yair Lotan; Robert S Svatek; Trinity J Bivalacqua; Robert L Grubb; Tracey L Krupski; Seth P Lerner; Michael E Woods; Brant A Inman; Matthew I Milowsky; Alan Boyd; F Peter Treasure; Gillian Gregory; David G Sawutz; Seppo Yla-Herttuala; Nigel R Parker; Colin P N Dinney
Journal:  J Clin Oncol       Date:  2017-08-23       Impact factor: 44.544

Review 7.  Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression.

Authors:  David J McConkey; Sangkyou Lee; Woonyoung Choi; Mai Tran; Tadeusz Majewski; Sooyong Lee; Arlene Siefker-Radtke; Colin Dinney; Bogdan Czerniak
Journal:  Urol Oncol       Date:  2010 Jul-Aug       Impact factor: 3.498

8.  Direct cytotoxicity produced by adenoviral-mediated interferon α gene transfer in interferon-resistant cancer cells involves ER stress and caspase 4 activation.

Authors:  Z Yang; X-Q Zhang; C N P Dinney; W F Benedict
Journal:  Cancer Gene Ther       Date:  2011-06-17       Impact factor: 5.987

9.  [Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer].

Authors:  B A Hadaschik; K Zhang; A I So; J C Bell; J W Thüroff; P S Rennie; M E Gleave
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

10.  An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis.

Authors:  Ge Jin; Hameem I Kawsar; Stanley A Hirsch; Chun Zeng; Xun Jia; Zhimin Feng; Santosh K Ghosh; Qing Yin Zheng; Aimin Zhou; Thomas M McIntyre; Aaron Weinberg
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.